截至发稿，华北制药市值为102亿元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 曾健辉） 每经AI快讯，华北制药（SH 600812，收盘价：5.94元）10月9日晚间发布公告称，截至本公告披露日， 公司及控股子公司对外担保总额约为17.01亿元，占2024年度经审计归属于上市公司普通股股东净资产 的31.56%，其中公司为控股子公司提供担保总额约为16.11亿元，占2024年度经审计归属于上市公司普 通股股东净资产的29.89%；对合并报表外单位担保金额为9000万元，占2024年度经审计归属于上市公 司普通股股东净资产的1.67%。 2025年1至6月份，华北制药的营业收入构成为：化学制剂药占比42.67%，化学原料药占比25.02%，生 物制剂占比16.71%，医药及其它物流贸易占比6.76%，医药中间体占比6.47%。 ...

Group 1 - The revenue composition of North China Pharmaceutical for the year 2024 is as follows: chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [1] Group 2 - As of the announcement date, the total external guarantees provided by North China Pharmaceutical and its subsidiaries amount to approximately 1.757 billion yuan, which represents 32.6% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The company has provided guarantees totaling approximately 1.667 billion yuan for its subsidiaries, accounting for 30.93% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [3]